SAN DIEGO, June 11, 2025 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced new and updated clinical data from its FT819 program for the treatment of moderate-to-severe systemic lupus erythematosus $(SLE)$. The data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain. The initial clinical profile of the FT819 off-the-shelf CAR T-cell program showed significant disease improvement in all five patients dosed, with the first patient reaching a 12-month follow-up and demonstrating durable drug-free remission. The company is expanding its clinical footprint in the U.S. and Europe and plans to discuss registrational strategies with the FDA for FT819 under its Regenerative Medicine Advanced Therapy (RMAT) designation. Fate Therapeutics has approximately 450 cryopreserved drug product bags of FT819 in inventory for patient treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。